利伐沙班与华法林在抗磷脂综合征高危患者中的比较
这项随机开放标签多中心非劣效性研究纳入120例三重阳性抗磷脂综合征高危患者,比较利伐沙班20 mg每日一次(根据肾功能调整至15 mg)与华法林(INR目标2.5)预防血栓栓塞事件、大出血和血管性死亡的效果。因利伐沙班组事件过多,试验提前终止;利伐沙班组11例(19%)事件,华法林组2例(3%)事件。
要点
- 利伐沙班组血栓栓塞事件7例(12%),华法林组0例。
- 利伐沙班组大出血4例(7%),华法林组2例(3%)。
- 利伐沙班在高危抗磷脂综合征患者中无获益且风险增加。
核心结论
- 在高危抗磷脂综合征患者中,利伐沙班相比华法林事件发生率增加,无获益且风险增加。
研究设计与样本
- 随机开放标签多中心非劣效性研究,采用盲法终点判定。
- 共纳入120例三重阳性(狼疮抗凝物、抗心磷脂抗体和抗β2糖蛋白I抗体同型三重阳性)高危抗磷脂综合征患者,利伐沙班组59例,华法林组61例。
- 利伐沙班20 mg每日一次(根据肾功能15 mg每日一次)对比华法林(INR目标2.5)。
- 平均随访569天。
- 因利伐沙班组事件过多,试验在纳入120例后提前终止。
主要发现
- 利伐沙班组11例(19%)事件,华法林组2例(3%)事件。
- 利伐沙班组血栓栓塞事件7例(12%)(4例缺血性卒中,3例心肌梗死),华法林组0例。
- 大出血共6例:利伐沙班组4例(7%),华法林组2例(3%)。
- 未报告死亡。
局限性
- 试验因利伐沙班组事件过多而提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared with warfarin in high-risk patients with thrombotic antiphospholipid syndrome. This is a randomized open-label multicenter noninferiority study with blinded end point adjudication. Rivaroxaban, 20 mg once daily (15 mg once daily based on kidney function) was compared with warfarin (international normalized ratio target 2.5) for the prevention of thromboembolic events, major bleeding, and vascular death in patients with antiphospholipid syndrome. Only high-risk patients triple positive for lupus anticoagulant, anti-cardiolipin, and anti-β2-glycoprotein I antibodies of the same isotype (triple positivity) were included in the study. The trial was terminated prematurely after the enrollment of 120 patients (59 randomized to rivaroxaban and 61 to warfarin) because of an excess of events among patients in the rivaroxaban arm. Mean follow-up was 569 days. There were 11 (19%) events in the rivaroxaban group, and 2 (3%) events in the warfarin group. Thromboembolic events occurred in 7 (12%) patients randomized to rivaroxaban (4 ischemic stroke and 3 myocardial infarction), whereas no event was recorded in those randomized to warfarin. Major bleeding occurred in 6 patients: 4 (7%) in the rivaroxaban group and 2 (3%) in the warfarin group. No death was reported. The use of rivaroxaban in high-risk patients with antiphospholipid syndrome was associated with an increased rate of events compared with warfarin, thus showing no benefit and excess risk. This trial was registered at www.clinicaltrials.gov as #NCT02157272.
引用
- Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018. PMID: 30002145. doi:10.1182/blood-2018-04-848333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。